



Erik Bloomquist, PhD

Merck

Erik Bloomquist is a senior principal scientist working in late-development statistics for Merck. Previously he worked for 13 years at the US FDA as a supervisory mathematical statistician in solid tumor oncology, with an emphasis on breast, obgyn, bladder, renal cell, and prostate malignancies. He was the 2022 FDA Statistical Association President and served as the ASA BIOP Regulatory-Statistics Workshop co-chair in 2023. He was elected ASA BIOP Section chair-elect for 2024. While at FDA, he was very interested in improving, promoting, and standardizing methodologies for treatment switch methodology in oncology trials and has conducted research into Bayesian methodologies for this area. His other research interests include methods for correlated survival distributions and auditing methodologies.